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Abstract: During the last three decades, an increasing understanding of the etiology, 
psychopathology, and clinical manifestations of schizophrenia spectrum disorders, in addition to 
the introduction of second-generation antipsychotics, has optimized the potential for recovery from 
the illness. Continued development of various models of psychosocial intervention promotes the 
goal of schizophrenia treatment from one of symptom control and social adaptation to an optimal 
restoration of functioning and/or recovery. However, it is still questionable whether these new 
treatment approaches can address the patients’ needs for treatment and services and contribute 
to better patient outcomes. This article provides an overview of different treatment approaches 
currently used in schizophrenia spectrum disorders to address complex health problems and a wide 
range of abnormalities and impairments resulting from the illness. There are different treatment 
strategies and targets for patients at different stages of the illness, ranging from prophylactic 
antipsychotics and cognitive–behavioral therapy in the premorbid stage to various psychosocial 
interventions in addition to antipsychotics for relapse prevention and rehabilitation in the later 
stages of the illness. The use of antipsychotics alone as the main treatment modality may be 
limited not only in being unable to tackle the frequently occurring negative symptoms and 
cognitive impairments but also in producing a wide variety of adverse effects to the body or organ 
functioning. Because of varied pharmacokinetics and treatment responsiveness across agents, 
the medication regimen should be determined on an individual basis to ensure an optimal effect 
in its long-term use. This review also highlights that the recent practice guidelines and standards 
have recommended that a combination of treatment modalities be adopted to meet the complex 
health needs of people with schizophrenia spectrum disorders. In view of the heterogeneity of 
the risk factors and the illness progression of individual patients, the use of multifaceted illness 
management programs consisting of different combinations of physical, psychological, and social 
interventions might be efficient and effective in improving recovery.
Keywords: schizophrenia, schizophrenia spectrum disorders, treatment, psychosocial interven-
tion, pharmacology, antipsychotics
Introduction
Schizophrenia and its spectrum disorders (all falling under the term “schizophrenia” in 
this article) are chronic remitting and disruptive disorders associated with significant 
abnormalities and the progressive deterioration of a wide variety of cognitive, psycho-
social, vocational, and behavioral functioning. The fourth edition of the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-IV) defines schizophrenia as a 
syndrome characterized by long duration, high relapse rate (.70%), bizarre delusions 
and behaviors, negative symptoms, and sometimes a few mood problems.1 The onset 
of symptoms typically occurs in adolescence and young adulthood, with a worldwide 
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estimate of its lifetime prevalence and incidence of 1.4–4.6 
and 0.16–0.42 per 1,000 persons annually, respectively.2,3 
A recent systematic review indicated that patients diagnosed 
with this disorder have a shorter lifespan than the average 
general population and are particularly at risk for suicide, 
increased physical risk (eg, limited exercise, poor diet, 
and obesity), and reduced access to medical treatment and 
healthcare services.4 In addition, 5%–8% of healthy people 
indicate an attenuated form of schizoid personality and 
schizophrenia-like symptoms, such as paranoid delusional 
thinking and auditory hallucination.5
Because of the complex health problems and wide range 
of abnormalities and impairments concerning schizophrenia, 
comprehensive and multimodal treatment approaches are 
considered and tested in different combinations, with the 
goal of reducing patients’ illness episodes and symptoms, 
as well as improving their functioning and quality of life 
in the longer term. Antipsychotic medications have been 
recommended consistently and continuously as the main-
stream and standard treatment for nearly all patients with 
schizophrenia, to provide them with a safe and therapeutic 
environment and effective symptom control since the intro-
duction of chlorpromazine (the first antipsychotic) in the 
1960s. In the last three to four decades, physical treatments 
such as electroconvulsive therapy (ECT; in the 1930s) and 
different approaches to psychosocial interventions such as 
psychoanalysis (in the 1950s), family therapy (in the 1960s), 
psychoeducation (in the 1980s), cognitive–behavioral ther-
apy (in the 1990s), and cognitive remediation (in the 2000s) 
have been introduced successively,7–14 and their comparative 
or combined efficacies for schizophrenia treatment have 
been increasingly evaluated in various clinical trials.8,10,12,13 
Recent systematic reviews and practice guidelines have 
recommended that as an adjunct to psychopharmacological 
treatment, psychosocial interventions designed to support 
both people with schizophrenia and their families should 
also be used to improve their rehabilitation, reintegration into 
the community, and recovery from the illness.6,15 Different 
modalities and combinations of psychosocial programs are 
recommended to address the complex individualized needs 
of these patients for multimodal care, particularly regarding 
relapse prevention, management of negative symptoms and 
cognitive dysfunction, and medication adherence.14,16 Despite 
increased recognition and demands for an individualized 
treatment plan and the integration of different intervention 
approaches to optimize patient outcomes, current psychiat-
ric treatments and services still involve practicing the same 
set of treatment approaches for each patient group in the 
course of illness. More clinical trials are recommended to 
examine the active ingredients of unimodal or integrated 
psychosocial interventions for schizophrenia that can be 
effective in enhancing recovery and other patient outcomes. 
There has also been increasing attention and demand for 
cost-effectiveness analyses of these interventions.
To gain a more in-depth and focused understanding of 
the effects and benefits of recent approaches to treatments 
for schizophrenia, we performed a comparative review, sum-
marized here, of the efficacy, safety, and tolerability of the 
current pharmacological and other medical treatments for 
these patients. In another article, we also performed a com-
parative review of the efficacy of approaches to psychosocial 
interventions for schizophrenia and a critical discussion about 
patient-focused perspectives of acceptance, benefits, and 
satisfaction in psychiatric care. Recommendations for best 
practices for continuity of schizophrenia care are also made. 
This article also provides an overview of the approaches to 
treatments across different stages of schizophrenia and the 
future direction of treatments for this illness.
Review of current approaches  
to medical treatments  
for schizophrenia
During the last two decades, the mainstream of medical treat-
ment for schizophrenia has remained the use of antipsychotics 
and/or other psychotropic medications. With increasing 
initiatives and evidence of the effectiveness of psychosocial 
interventions for schizophrenia, the highly structured or 
manualized (eg, cognitive–behavioral and psychoeducation 
programs) and a few integrated programs (eg, the Schizo-
phrenia Patient Outcomes Research Team Programs and the 
Recovery After an Initial Schizophrenia Episode Early Treat-
ment Program in the United States),17,18 used as an adjunct to 
antipsychotics, have indicated positive patient outcomes. On 
the basis of several large-scale randomized controlled trials, 
single and multiple types of antipsychotics, or polypharmacy 
in combination with other psychotropic drugs, are consid-
ered useful in schizophrenia treatment. The introduction of 
second-generation antipsychotics has further improved the 
desired effects of these medications for schizophrenia care 
and, more important, reduced their undesirable effects such 
as extrapyramidal adverse effects, mortality, and metabolic 
disorder. Before exploring the recent changes or improve-
ments needed in schizophrenia treatment and rehabilitation, it 
is important to review and understand the current knowledge 
about pharmacological and other medical treatments for 
schizophrenia sufferers.
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Pharmacological treatment
First- and second-generation 
antipsychotics
More than 70 antipsychotics have been introduced. They are 
mainly categorized into first- and second-generation agents 
and share a similar pharmacological mechanism in blocking 
the dopamine D-2 receptors.19 Their blocking mechanisms 
or actions are linked to their efficacy against positive and 
disorganization symptoms of schizophrenia.11–13
The first-generation antipsychotics (FGAs), or typi-
cal antipsychotics (eg, chlorpromazine, fluphenazine, and 
haloperidol, included in the World Health Organization’s 
list of Essential Medications in 2009),20 were first intro-
duced for the treatment of schizophrenia in the 1950s. The 
second- generation (atypical) antipsychotics (eg, clozapine, 
olanzapine, and risperidone) introduced in the last three 
decades were believed to be more efficacious and toler-
able than the FGAs, and a few have progressively replaced 
the older FGAs to become the first-line prescription or the 
standard of care. To capture the research evidence or drug 
trials on  antipsychotics, full-text articles published in English 
between 1966 and 2010 were searched for in CINAHL, 
MEDLINE, EMBASE, The Cochrane Library, Cochrane 
Schizophrenia Group’s Register, Biological Abstracts, 
Sociological Abstracts, Sociofile, and PsycLIT. Participants 
included people with schizophrenia, schizophrenia-like 
psychoses such as schizophreniform and schizoaffective dis-
orders, and psychotic disorders such as delusional disorder, 
nonaffective psychosis, or dual diagnosis. The main out-
comes identified from the reviewed articles mainly involved 
mental state, global functioning, and adverse events.
Thirteen systematic reviews on the efficacy of FGAs 
using a randomized controlled trial design were found 
(Table 1). With similar intended outcomes, several outcome 
measurement tools were commonly used, including the 
Clinical Global Impression, Global Assessment Scale, and 
Global Assessment of Functioning scale for patients’ global 
functioning; the Brief Psychiatric Rating Scale, Positive 
and Negative Syndrome Scale, Scale for the Assessment 
of Negative Symptoms, and Scale for the Assessment of 
Positive Symptoms for their mental state or symptom sever-
ity; and the Involuntary Movement Scale, Extrapyramidal 
Symptom Rating Scale, Extrapyramidal Rating Scale, and 
Simpson and Angus Scale for the adverse effects of medi-
cation used. Most of the clinical trials (.70%) evaluated 
the medication effects over a short period of time (eg, up 
to 12 weeks), whereas a few (,10%) involved a long-term 
follow-up (eg, .1 year).
The first FGA invented – chlorpromazine, has become 
the well-established and benchmark treatment for people 
with schizophrenia to facilitate their  deinstitutionalization21 
and has been used for more than 40 years. Nevertheless, 
the reviewed literature showed that the incidence and 
average dose of chlorpromazine prescribed to people with 
schizophrenia has been decreasing.22 Other commonly 
used FGAs such as trifluoperazine, thioridazine, sulpiride, 
pimozide, perphenazine, and fluphenazine were tested 
and confirmed to have similar and satisfactory efficacy in 
symptom reduction – mainly for positive symptoms (eg, 
delusions and hallucinations).23–28 However, there was 
limited evidence to support their efficacy at lower doses or 
in short-term treatment.28–31 Major adverse events induced 
by FGAs generally include sedation, movement disorders, 
endocrine disturbance, and metabolic and electrocardiogram 
changes.24,25,28,32
Most of all, FGAs are a relatively low-cost treatment and 
commonly used medication; however, there is little evidence 
to support their efficacy in reducing negative symptoms 
(eg, anhedonia, loss of volition, and social withdrawal) and 
cognitive functioning, which may contribute much to the 
functional disability of people with schizophrenia.26,29,33 It is 
generally concluded that there is similar satisfactory clini-
cal efficacy in terms of mental state and global functioning 
across the FGAs and second-generation antipsychotics.34–37 
However, a few trials indicate the superiority of individual 
second-generation agents over the FGAs in specific illness 
condition or patient outcomes.29,33,37,38 In two meta-analyses 
of placebo-controlled trials,39,40 haloperidol was reported 
to be less effective in reducing symptoms and/or relapse 
than certain second-generation agents (eg, clozapine and 
olanzapine).
Second-generation (or atypical) antipsychotics were 
believed to have good antipsychotic properties and  minimal 
adverse effects compared with those noted with the use of 
FGAs. Some of them have been shown to be more  efficacious 
and less problematic in terms of sedative and neurologi-
cal effects than FGAs.41,42 Using the same databases and a 
similar procedure as the literature search on FGAs presented 
earlier, 12 systematic reviews (between 1966 and 2010) 
have been conducted to compare the effects among second-
generation antipsychotics and the effects between these 
second-generation agents and FGAs or a placebo (Table 2). In 
addition to the main patient outcomes used (ie, mental state, 
global functioning, and relapse), several other psychosocial 
outcomes were usually compared across studies, including 
level of depression, acceptability of treatment (eg, dropout 
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Current treatments for schizophrenia spectrum disorders
rate and patient dissatisfaction), inability to work, family 
burden, and social and cognitive functioning. Therefore, 
there are a wider variety of outcome measurements than 
used in previous studies, such as depression (eg, the Calgary 
Depression Scale, the Hamilton Rating Scale for Depres-
sion, or the Montgomery Asberg Depression Rating Scale), 
quality of life (eg, the Quality of Life Scale, the Schizo-
phrenia Quality of Life Scale, the Subjective Well-being 
on Neuroleptics [Antipsychotics] Scale, or the Personal and 
Social Performance Scale), and patient satisfaction (eg, the 
Nurses Observational Scale Inpatients Evaluation) measures. 
Similar to those receiving FGAs, most of the clinical trials 
evaluated the short-term effects (up to 12 weeks) of the 
second-generation antipsychotics, even though a few long-
term evaluations appear promising.39,40
A few systematic reviews also indicated that the con-
trolled trials of second-generation antipsychotics have mainly 
tested only a few kinds, including risperidone, olanzapine, 
quetiapine, loxapine, sertindole, aripiprazole, and amisul-
pride, and mostly compared them with placebo controls.43–50 
The reviews concluded that second-generation antipsychotics 
had similar effects to FGAs in terms of reduction of positive 
symptoms. The treatment efficacy of both FGAs and second-
generation antipsychotics varies in terms of stages of the 
illness, with first-episode schizophrenia responding faster 
and better than at later illness stages.35,41,51 Nevertheless, most 
of the second-generation antipsychotics had comparatively 
fewer and lower levels of adverse effects such as movement 
disorders and cardiac and sedative problems than FGAs. 
Clozapine, the first second-generation antipsychotic, has 
been found to be particularly effective in treating refractory 
patients and reducing suicidality.36,41 A recent meta-analysis 
comparing nine second-generation antipsychotics with the 
FGAs (eg, chlorpromazine, fluphenazine and haloperidol) 
for overall efficacy concluded that four second-generation 
antipsychotics (namely, amisulpride, clozapine, olanzapine, 
and risperidone) were better than the FGAs, with small 
to medium effect sizes (ie, 0.13–0.52).37 The four second-
generation antipsychotics have been shown to induce fewer 
extrapyramidal adverse effects than the low-potency FGAs. 
Although olanzapine can induce more weight gain and pro-
duction of prolactin, it is shown to exert a persistent treatment 
effect over other second-generation antipsychotics in chronic 
schizophrenia.37,52
A recent Cochrane’s systematic review was published on 
nine randomized, placebo-controlled trials of aripiprazole, 
which is one of the newer second-generation antipsychotics. 
Its main results indicated that aripiprazole can significantly So
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re
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 c
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 t
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l s
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 m
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 d
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at
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ra
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ur
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ol
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 c
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at
io
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of
 s
tu
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fo
llo
w
-u
p,
 w
ith
 t
ri
al
s 
ra
ng
in
g 
fr
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 s
ho
rt
-t
er
m
, u
p 
to
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2 
w
ee
ks
, t
o 
m
ed
iu
m
-t
er
m
, 1
3–
24
 w
ee
ks
, t
o 
lo
ng
-t
er
m
, m
or
e 
th
an
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4 
w
ee
ks
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A
bb
re
vi
at
io
ns
: F
G
A
s,
 fi
rs
t-
ge
ne
ra
tio
n 
an
tip
sy
ch
ot
ic
s;
 R
C
T
s,
 r
an
do
m
iz
ed
 c
on
tr
ol
le
d 
tr
ia
ls
; v
s,
 v
er
su
s.
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ra
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re
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 o
f s
tu
dy
  
or
 fo
llo
w
-u
pa
S
u
m
m
ar
y 
o
f 
m
ai
n
 fi
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d
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 d
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; m
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os
pi
ta
l  
or
 o
ut
pa
tie
nt
 s
et
tin
g
Fo
llo
w
-u
p:
 u
p 
 
to
 1
2 
w
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 c
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 c
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 c
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 c
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f d
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e
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ri
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pr
az
ol
e 
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N
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,5
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; m
ai
nl
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uc
te
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a 
ho
sp
ita
l o
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ie
nt
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et
tin
g
ei
gh
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m
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 t
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C
T
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th
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w
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 r
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 b
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 r
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an
d 
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ol
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tio
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 c
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re
ct
ed
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T
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te
rv
al
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C
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(r
ep
re
se
nt
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th
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po
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ri
za
tio
n 
an
d 
re
po
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ri
za
tio
n 
of
 t
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le
ft 
an
d 
ri
gh
t 
ve
nt
ri
cl
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r 
ve
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.
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w
er
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 t
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tr
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 d
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y,
 s
er
vi
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d 
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d 
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gn
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.
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ri
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az
ol
e 
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be
 e
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ct
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ho
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 m
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iu
m
-t
er
m
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re
at
m
en
t.
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 T
he
re
 w
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 h
ig
h 
at
tr
iti
on
 in
  
al
l s
tu
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es
 (
.
30
%
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C
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ar
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xa
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ne
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pl
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eb
o,
  
se
co
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-g
en
er
at
io
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an
tip
sy
ch
ot
ic
s,
  
an
d/
or
 F
G
A
s
N
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,3
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ll 
 
co
nd
uc
te
d 
in
  
ho
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ls
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llo
w
-u
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om
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or
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te
rm
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 m
on
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ng
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er
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)
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te
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C
T
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 o
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G
A
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ng
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C
T
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re
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ne
ra
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er
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 r
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se
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w
 p
at
ie
nt
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ut
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.
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un
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e 
dr
ug
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 s
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r 
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ve
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e 
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G
A
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d 
th
at
 t
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w
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ho
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sy
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ot
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 Lo
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 c
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 b
e 
ef
fe
ct
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e 
fr
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ng
-t
er
m
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at
m
en
t 
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ch
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, b
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 s
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r 
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fic
ac
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to
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w
 o
th
er
 F
G
A
s 
an
d 
 
se
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nd
-g
en
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at
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an
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sy
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ot
ic
s.
• 
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m
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 c
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e 
ex
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al
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e 
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m
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w
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 o
th
er
 s
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ra
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an
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ot
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itr
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5
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si
do
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N
 =
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; m
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se
tt
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llo
w
-u
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om
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da
ys
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sh
or
t-
te
rm
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to
 1
8 
m
on
th
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(lo
ng
-t
er
m
)
• 
 Lu
ra
si
do
ne
 w
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 s
ho
w
n 
to
 b
e 
ef
fic
ac
io
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 a
nd
 t
ol
er
ab
le
  
w
ith
 fo
od
 a
nd
 h
ad
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 h
ig
hl
y 
fa
vo
ra
bl
e 
m
et
ab
ol
ic
 p
ro
fil
e.
• 
 A
ka
th
is
ia
 o
r 
Pa
rk
in
so
ni
sm
 w
as
 r
ep
or
te
d 
in
 m
os
t 
R
C
T
s.
• 
 A
dd
iti
on
al
 d
at
a 
w
er
e 
ne
ce
ss
ar
y 
 
to
 s
up
po
rt
 it
s 
lo
ng
-t
er
m
 e
ffi
ca
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 a
 m
ai
nt
en
an
ce
 t
re
at
m
en
t.
D
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ga
n 
et
 a
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O
la
nz
ap
in
e 
vs
 F
G
A
s,
  
se
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nd
-g
en
er
at
io
n 
 
an
tip
sy
ch
ot
ic
s,
  
an
d/
or
 p
la
ce
bo
N
 .
 1
0,
00
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m
ai
nl
y 
co
nd
uc
te
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 t
he
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pi
ta
l o
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ou
tp
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ie
nt
 s
et
tin
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el
ev
en
 c
on
du
ct
ed
  
in
 n
on
id
en
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ed
  
se
tt
in
gs
31
 s
ho
rt
-t
er
m
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23
 m
ed
iu
m
-t
er
m
,  
an
d 
tw
o 
lo
ng
-t
er
m
  
tr
ia
ls
• 
 Si
xt
ee
n 
R
C
T
s 
sh
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ed
 h
ig
h 
at
tr
iti
on
 b
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w
ee
ks
  
in
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ot
h 
ol
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pi
ne
 a
nd
 p
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ce
bo
/F
G
A
s;
 fo
ur
 fo
un
d 
 
th
e 
dr
ug
 a
s 
ef
fe
ct
iv
e 
as
 F
G
A
s.
• 
 Fo
ur
 fo
un
d 
ol
an
za
pi
ne
 t
o 
ca
us
e 
fe
w
er
 m
ov
em
en
t 
 
di
so
rd
er
s 
bu
t 
m
or
e 
w
ei
gh
t 
ga
in
 fr
om
 3
 t
o 
12
 m
on
th
s 
 
of
 t
re
at
m
en
t.
• 
 el
ev
en
 r
ec
or
de
d 
th
at
 2
3%
 o
f p
eo
pl
e 
in
 t
ri
al
s 
of
  
ol
an
za
pi
ne
 a
nd
 o
th
er
 s
ec
on
d-
ge
ne
ra
tio
n 
an
tip
sy
ch
ot
ic
s 
 
le
ft 
by
 8
 w
ee
ks
, a
nd
 4
8%
 b
y 
3 
to
 1
2 
m
on
th
s.
• 
 M
os
t 
st
ud
ie
s 
re
po
rt
ed
 v
er
y 
hi
gh
  
at
tr
iti
on
 in
 b
ot
h 
ol
an
za
pi
ne
  
an
d 
pl
ac
eb
o/
FG
A
/o
th
er
 s
ec
on
d-
 
ge
ne
ra
tio
n 
an
tip
sy
ch
ot
ic
 g
ro
up
s,
  
ra
ng
in
g 
fr
om
 .
30
%
 b
y 
6 
w
ee
ks
  
to
 5
0%
 b
y 
12
 m
on
th
s.
• 
 T
he
re
 w
as
 s
im
ila
r 
ef
fic
ac
y 
 
to
 o
th
er
 s
ec
on
d-
ge
ne
ra
tio
n 
 
an
tip
sy
ch
ot
ic
s 
in
 r
el
ap
se
  
pr
ev
en
tio
n 
an
d 
re
du
ct
io
n 
 
of
 p
os
iti
ve
 s
ym
pt
om
s,
 b
ut
  
no
 n
ot
ab
le
 b
en
efi
t 
in
 n
eg
at
iv
e 
 
sy
m
pt
om
s.
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Current treatments for schizophrenia spectrum disorders
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at
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 p
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 c
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 p
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 p
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at
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.
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at
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 m
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at
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at
io
n 
an
tip
sy
ch
ot
ic
s  
an
d 
m
os
t 
FG
A
s 
in
 r
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 p
os
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 p
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 m
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 d
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 d
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; c
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 m
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decrease relapse in both the short-term (,3 months; n = 310; 
risk ratio, 0.59 [95% confidence interval, 0.45–0.77]) and 
medium-term (3–6 months; n = 310; risk ratio, 0.66 [95% 
confidence interval, 0.53–0.81]) when compared with pla-
cebo controls.48 Aripiprazole can also produce less attrition 
and better compliance with study protocol (n = 2,275; risk 
ratio, 0.74 [95% confidence interval, 0.59–0.93]), and lower 
risk for raised prolactin level than that expected from the 
placebo (n = 305; risk ratio, 0.21 [95% confidence interval, 
0.11–0.37]).
Apart from oral medication, inhaled loxapine is consid-
ered a well-tolerated and rapid acute treatment for agitation 
but needs further longer-term controlled trials to verify 
its efficacy.53 Studies on relatively new second-generation 
antipsychotics such as ziprasidone have shown that their 
efficacy on positive symptoms is much better than that of 
other second-generation antipsychotics, whereas ziprasidone 
and lurasidone are clinically valuable and suggested to be 
taken with food.34,54
Most of the reviews appear not only to be concerned 
with their clinical efficacy and tolerability but also to pay 
more attention to psychosocial functioning and cognitive 
performance in activities of daily living. Among few sys-
tematic reviews/meta-analyses of the effect of FGAs on 
cognition in schizophrenia, one meta-analysis by Mishara 
and Goldberg55 included 34 randomized, placebo-controlled 
trials and suggested that most FGAs can provide modest to 
moderate benefits (ie, effect sizes ranged from 0.13 to 0.29) 
in multiple cognitive domains, whereas motor function was 
affected negatively. Although most of the newest second-
generation antipsychotics have shown similar treatment 
efficacy in improving mental state and general functioning, 
they have not yet shown significant differences or consis-
tent effects on reducing negative symptoms or cognitive 
dysfunction.36,56–60 Although one review reported that social 
functioning was better for people with schizophrenia tak-
ing the newer second-generation antipsychotics,36 most 
of the controlled trials only evaluated their efficacy over 
3–6 months, and very high attrition rates and limited long-
term effects on cognitive functioning, quality of life, service 
use and satisfaction, and other psychosocial functioning and 
behaviors were noted.36,57–62 Therefore, it is difficult to draw 
conclusions with regard to these second-generation antipsy-
chotics, both on most patient outcomes, particularly in the 
longer-term, or on their cost benefits.46,49,63 Nevertheless, it 
is noteworthy that a recent population-based cohort study 
in Finland with 11 years of follow-up indicated decreased 
rates of mortality with perphenazine when compared with 
the other FGAs and a few second-generation antipsychotics 
and that only the use of clozapine was associated with lower 
rates of overall mortality.64
In conclusion, FGAs and second-generation antipsychot-
ics are found to be similar and robust in treatment efficacy 
among acute and sometimes chronic schizophrenia, par-
ticularly against positive and disorganization symptoms.65 
Their efficacy varies according to the course or stage of the 
illness; people with first-episode schizophrenia can respond 
faster and better to antipsychotics than those at later stages 
of the illness. In contrast, neither is effective in reducing 
negative symptoms, and they can even worsen the negative 
symptoms associated with extrapyramidal adverse effects 
(eg, antipsychotic-induced dysphoria).66 The efficacy of 
FGAs and second-generation antipsychotics on cognitive 
and social functioning, as well as other longer-term effects 
such as mortality and quality of life, are inconsistent. 
However, individual antipsychotics have shown significant 
differential efficacy in particular illness conditions and 
related problems, as well as different adverse effects. All 
of them reveal their onset of action within a few days and 
achieve optimal antipsychotic effect over the course of sev-
eral weeks. Although antipsychotics substantially decrease 
patients’ relapse from schizophrenia, it is not possible to 
ensure medication or other treatment compliance; thus, long-
term injectable antipsychotics (eg, oil-based fluphenazine 
decanoate) may be considered. In view of the significantly 
varied pharmacokinetics of and treatment responses to 
antipsychotics among people with schizophrenia, it is rec-
ommended not only to examine the overall efficacy within 
and across patient groups but also to consider the efficacy 
of each antipsychotic medication for each individual patient 
when it is prescribed.67,68
Safety and tolerability  
of antipsychotics
Antipsychotics, particularly FGAs, can have a wide range of 
undesirable and adverse effects on patients, mainly includ-
ing neurological, metabolic, cardiovascular, hematological, 
endocrine, and genitourinary disturbances. In addition, they 
differ from one to another in the levels and nature of these 
adverse effects. Although a few had less-extreme adverse 
effects (eg, perphenazine and sulpiride),26,29 all of the reviews 
indicated that the profile of adverse events concerning these 
adverse effects found in most FGAs (eg, acute extrapyramidal 
symptoms and tardive dyskinesia) is substantial and of major 
concern, thus reducing patients’ medication compliance and 
treatment efficacy.23,24,26–30,33
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Nevertheless, most second-generation antipsychotics 
have comparatively fewer and lower levels of adverse effects 
such as movement disorder, increased prolactin, and cardiac 
and sedative problems, than FGAs. In contrast, there may be 
higher risks for dizziness, sedation, weight gain, substantial 
increases in serum prolactin, and tachycardia for individual 
second-generation antipsychotics.44–48,69 However, there has 
not been any systematic work or classification to categorize 
or distinguish the risks of these adverse effects between antip-
sychotics, particularly the second-generation antipsychotics. 
As these adverse effects may affect aspects of patients’ lives 
and treatment adherence and satisfaction, more work on 
such classification of antipsychotics in terms of their types 
or levels of adverse effects should be considered.
Clozapine, the first second-generation antipsychotic, does 
not show any extrapyramidal effects or tardive dyskinesia, 
but other serious adverse effects such as agranulocytosis 
and metabolic syndrome have limited its utility. In contrast, 
Tiihonen et al64 reported that clozapine was associated with 
a significantly lower mortality rate than other antipsychot-
ics and also concluded that a lower mortality rate could 
be associated with a longer-term use of antipsychotics. 
Although clozapine is expected to have higher risks of a few 
adverse effects, inducing increased mortality, the researchers 
explained it has been shown to demonstrate very positive 
effects on symptom reduction and treatment compliance. 
Studies on relatively new second-generation antipsychotics 
such as ziprasidone have shown that they had fewer adverse 
effects in terms of metabolic profile (eg, metabolic distur-
bance and weight gain) and cognitive functioning and that 
their effects on positive symptoms are much better than those 
of other second-generation antipsychotics.34,44 Lurasidone 
has also indicated a highly favorable metabolic profile but 
is still not free from adverse events such as akathisia and 
Parkinson’s syndrome.35
A large, 25-year cohort study measuring the mortality 
of 370 people with schizophrenia in Southampton, United 
 Kingdom, reported that the cohort had an all-cause stan-
dardized mortality ratio of 289 (95% confidential interval, 
247–337), indicating small and nonsignificant changes 
between 1981 and 2006 but falling sharply from 376 
(1981–1986) to 264 (1986–1991) in the first 10 years.70 This 
considerable reduction of mortality rate in the 1980s was 
mainly a result of a significant fall in unnatural deaths over 
the period (ie, the mortality ratio of suicide decreased from 
6,110 in 1981–1986 to 0 in 1986–1991). In addition, the 
findings of the study support previous findings that people 
with schizophrenia have a mortality between two and three 
times that of the general populations,74 as well as raise con-
cern about the cardiovascular mortality of schizophrenia, 
which has significantly increased during the past 25 years.80 
 Nevertheless, the effects of clozapine and other second-
 generation antipsychotics on mortality and treatment compli-
ance among patients with schizophrenia reveal the difficulties 
in linking medium- or long-term patient outcomes with 
short-term drug effects; that is, whether symptom reduction 
can be mainly explained by the efficacy of antipsychotic use. 
It is therefore recommended that more longitudinal research 
be conducted with longer-term follow-up on predictors or 
mediators of patient outcomes in schizophrenia in relation 
to antipsychotic use.
Patterns in medication use:  
mono- and polypharmacy
Treatment of people with schizophrenia who are resistant 
to treatment and have persistent cognitive and negative 
symptoms remains a challenge to most clinicians. Many 
controlled trials of antipsychotics and their combined use 
with other psychotropic drugs (eg, acetylcholinesterase 
inhibitors, glutamatergic agents, antidepressants, benzo-
diazepines, and anticonvulsants) have been carried out in 
people with treatment-resistant and chronic schizophrenia, 
particularly on the means for improvement of negative 
symptoms, quality of life, and social function. However, 
very limited and weak evidence has been shown to confirm 
whether a particular antipsychotic medication or any of the 
combination strategies used could be efficacious in main 
patient outcomes and/or superior to the others in the treat-
ment of schizophrenia,71–76 and none can be considered a 
robust treatment or prevention prescription for schizophrenia 
care.77–84 Nevertheless, psychosocial interventions, together 
with pharmacological treatment, are recommended to be the 
most effective strategies in the treatment and rehabilitation 
of people with schizophrenia.85
Despite such inconclusive and weak evidence on 
pharmacological agents to control negative symptoms or 
treatment-resistant cases, some combinations of medica-
tion use have indicated modest to satisfactory benefits in 
targeting specific psychotic symptoms.71,86–88 For instance, 
anticonvulsants such as valproic acid and carbamazepine are 
found to be useful as adjuncts to antipsychotics in treating 
aggression and impulsivity in schizophrenia,75,76 and adjunc-
tive antidepressants can be useful in treating depression and 
anxiety symptoms and in reducing craving in comorbid 
substance use.83,84,89  Interestingly, a double-blinded, multi-
center randomized  placebo-controlled trial on the effects 
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of a Warm- Supplementing Kidney Yang capsule containing 
13 traditional Chinese herbs indicated that the capsule had 
demonstrated significant improvements in quality of life 
and social function, as well as in depression symptoms, in 
200 patients with schizophrenia at a 4-week follow-up.90
Depot injections have also been used extensively for con-
trolling treatment noncompliance and long-term maintenance 
therapy, thus reducing the risk of relapse.91–93 Reviews on 
second-generation antipsychotic or FGA depots (eg, bro-
mperidol decanoate, haloperidol depot, risperidone depot, 
and fluphenazine decanoate) versus oral antipsychotic drugs 
and placebo indicated that patients with FGA depots had few 
relapses and fewer oral medications, even though the differ-
ence did not reach statistical significance.94–96 Together with 
similar levels of adverse effects found in depot medications, 
it was also difficult to conclude that a particular depot was 
no better than any other depot or oral medication.96 Despite 
showing similar clinical efficacy between oral and depot 
medications, depot injections can avoid frequent regular 
administration of and nonadherence to oral medication, 
rendering them more desirable for maintenance or compli-
ance therapy.
Pharmacological treatment  
used in different developmental  
stages of life
During the last decade, there have been an increasing number 
of randomized controlled trials of the efficacy and safety 
of the FGAs and secondary-generation antipsychotics in 
children and adolescents with schizophrenia, involving 
double-blind, placebo-controlled, or open-labeled design and 
short- to medium-term follow-up (ie, 4–8 weeks).97–103 Those 
aged 12–17 years were usually included in the controlled 
trials, and a wide variety of second-generation antipsychot-
ics such as quetapine,97 risperidone,98 paliperidone,99 and 
olanzapine100 were tested. A few main patient outcomes were 
commonly used, including global functioning, symptom 
severity, and quality-of-life assessment; however, few of the 
studies involved any long-term follow-up (ie, .8 weeks).97–103 
In addition, a few types of treatment-emergent adverse events 
specifically for the second-generation antipsychotic used 
were observed (eg, metabolic and endocrine abnormalities 
for olanzapine and somnolence, agitation and electrocardio-
gram (ECG) and ophthalmic abnormalities for quetiapine). 
Similar to other age groups, most of the antipsychotics have 
had positive benefits for adolescents on reducing psychotic 
symptoms and global functioning, and the treatment was 
well- tolerated with acceptable levels of adverse events in low 
and medium  dosages. None of the FGAs or second-genera-
tion antipsychotics has shown its superiority over the others, 
and the benefits of polypharmacy to any psychotic symptoms 
and comorbidities such as mood disorders for adolescents 
are also inconclusive.102,103 Nonetheless, it is suggested that 
antipsychotics are generally better tolerated and more effec-
tive in early psychosis.
Interestingly, a case study on a 17-year-old patient with 
intractable catatonic schizophrenia showed moderate effects 
in the resumption of spontaneous movement as a result of 
ECT as an adjunct to clozapine treatment.104 The researchers 
suggested that appropriate combinations of antipsychotic 
medication and other treatment modalities could also be con-
sidered in young patients, although it would be unusual.
It is estimated globally that about 23% of hospitalized 
patients with schizophrenia are older than 40 years and that 
more than 0.1% of elderly people have a diagnosis of late-
onset schizophrenia.105 Very few studies have been done on 
those aged more than 65 years, and thus there are inadequate 
data and evidence to support any guidelines for treatment 
of late-onset schizophrenia or to serve these older patients’ 
quality of life, functioning, and service use.105,106
ECT and other treatments
ECT, in which clonic seizure is electrically induced in anes-
thetized patients for therapeutic effects such as improved 
mood and volition, was commonly used in the 1930s–1970s. 
One of the major patient groups for this treatment com-
prised those with schizophrenia or schizoaffective disorder. 
Although recent research findings are limited, ECT is con-
sidered an alternative treatment for those with unfavorable 
responses to antipsychotics alone after receiving different 
courses of medical or psychological treatment, and/or those 
with very strong suicidality and catatonic features.107,108 It 
is an effective adjunct to clozapine in treating refractory 
schizophrenia.104 There is certainly no strong or conclu-
sive evidence to suggest that ECT alone or as an adjunct 
to antipsychotics is superior to antipsychotics alone or 
to any combination of different treatment modalities for 
schizophrenia. In addition, ECT may cause short-term, or 
occasionally long-term, memory impairment and leaves 
many unanswered questions about its role and mechanisms 
in the treatment of schizophrenia.108 Similarly, transcranial 
magnetic stimulation (a procedure that uses magnetic fields 
to stimulate the depolarization or hyperpolarization of the 
neuron cells in the cortical regions of the brain) has shown 
preliminary positive evidence in treating refractory negative 
symptoms and auditory hallucinations.109,110
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It is also believed that Chinese herbal medicine pro-
duces progressive positive changes in physiological and 
mental state and fewer adverse effects when compared with 
Western medicine. The adverse effects of antipsychotics-
induced  psycho- and physiopathological changes (eg, 
dysfunctions of the body organs and sleep–wake cycle) in 
the body can be treated with such herbal medicine, which is 
considered to promote the Yin–Yang balance and maintain a 
homeostatic environment of the internal bodily condition.111 
 Electroacupuncture for schizophrenia sufferers with auditory 
hallucination who were partially or fully nonresponsive to 
risperidone monotherapy was studied with a small-sized 
sample. The results showed that there was no significance 
difference between the two treatment modalities in terms of 
adverse effects, whereas electroacupuncture could induce 
a satisfactory improvement in auditory hallucination and a 
few other positive symptoms.112 Nevertheless, no conclusions 
were drawn on the potential efficacy of traditional Chinese 
medicine in treating schizophrenia, because of the very 
limited empirical evidence on this topic.
Approaches to treatment  
for schizophrenia from prodromal 
to later stages of illness
Various pharmacological treatments and psychosocial inter-
ventions for people with schizophrenia have been developed 
and evaluated over the last four decades. Although these 
innovative treatments and interventions have aroused much 
attention and accelerated deinstitutionalization, moderately 
low improvements in recovery, community-based rehabili-
tation, and quality of life among people with schizophrenia 
have been the result. The modest nature of these improve-
ments may be because of the limited accessibility and 
availability of different alternatives or combined treatments 
and/or very advanced pathological and severe symptoms of 
patients when they present to and seek treatments from the 
mental healthcare system.66 More important, current treat-
ments demonstrate that fairly positive patient outcomes in 
schizophrenia can be explained by the fact that most treat-
ment plans do not vary across the course of the illness, even 
though different psychopathological processes are closely 
linked with different stages of schizophrenia. The three 
main stages of schizophrenia can include the premorbid and 
prodromal stage, the first onset or episode of acute illness, 
and the later stages of ongoing management, rehabilitation, 
and recovery.
To better understand the common treatment modali-
ties, their main purposes, and their levels of effectiveness 
and reproducibility, a summary of current approaches to 
treatments for schizophrenia specific to the three stages of 
schizophrenia mentioned earlier is presented in Table 3. In 
the summary of the current body of knowledge about phase-
specific treatment approaches (Table 3), it is essential to note 
that the mainstay treatments and management strategies of 
schizophrenia seem to have evolved at a slow pace and are 
highly reliant on antipsychotic agents as the basic treatment 
for all schizophrenia sufferers. The effectiveness and/or cost-
benefit analysis of most psychosocial interventions used, as 
well as their superiority and therapeutic components, are 
somewhat inconsistent and inconclusive.
Throughout the course of schizophrenia, more than 70 types 
of antipsychotic agents classified into first- and second-
 generation groups can be useful for symptom  management. 
Nearly all antipsychotics share similar properties to block the 
dopamine D-2 receptor in terms of different potencies relating 
to their affinity for the receptor.19 They show no major differ-
ences in clinical efficacy for the overall schizophrenia group 
in meta-analyses of recent placebo-controlled studies.40,66,113 
Although antipsychotics are found to significantly reduce a 
wide range of psychotic symptoms, and thus relapses, their 
effects on psychosocial functioning, cognitive and vocational 
skills, and longer-term community living skills in schizo-
phrenia are vague and inadequately studied.114,115 It is also 
essential to point out that this similar overall efficacy reported 
in schizophrenia is not equal to and does not signify the same 
desirability or adverse effects, safety, tolerance, and/or other 
clinical responses in each individual patient.
Nevertheless, new pharmacological treatments for schizo-
phrenia have been merging as a result of better understanding 
of its etiology and pathophysiology and the specific targeting 
of individual symptom domains.114 For instance, N-methyl-
D-aspartate glutamate receptor agonists and glycine site ago-
nists have been used in combination with antipsychotics, or 
the activating agents of the metabotropic glutamate 2/3 recep-
tors, and can be successful in reducing negative symptoms.115 
Alpha 7 nicotinic receptor agonists, dopamine 1 receptor 
agonists, and modulators of  glutamatergic aminomethyl-
phosphonic acid (AMPA) receptors have been found to be 
useful in reducing cognitive impairments in schizophrenia.116 
Therefore, different pharmacological treatment plans can 
be designed to target different pathophysiological processes 
relevant to different stages of schizophrenia.
For the premorbid phase (Table 3), most people with 
psychotic features experience a lengthy prodromal period 
of nonspecific symptoms and slowly progressive functional 
impairments before the full emergence of the diagnostic 
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psychotic symptoms. The development of higher levels 
of dysfunction and disability during the prodromal period 
creates major inhibitory factors influencing recovery, thus 
providing very strong rationale for premorbid assessment 
and interventions. To promote accurate and valid assess-
ment of high-risk individuals or groups, specific scales are 
being developed, such as the Bonn Scale for the Assessment 
of Basic Symptoms and the Comprehensive Assessment of 
At-Risk Mental State, as well as the Scale of Prodromal 
Symptoms.117,118 Without any of the strategies currently used, 
specific population-based prevention and assessment efforts 
should be made, targeting high-risk groups with mild early 
psychotic symptoms. Most important, identification of risk 
factors and symptomatic indicators is critical for accurately 
selecting at-risk persons and matching them to the most 
appropriate preventive treatment. As suggested by Birch-
wood, Todd, and Jackson’s hypothesis of critical periods 
of onset and early intervention of psychosis,119 therapeutic 
interventions such as cognitive–behavioral therapy and asser-
tive outreach services are most effective if they are offered 
at the earliest possible moment during the most vulnerable 
periods of illness onset.120,121 Research evidence suggesting 
that these cognitive and behavioral interventions can help 
people in the prodromal stage of schizophrenia is emerging, 
but is as yet inconclusive.122
In acute-episode or first-onset schizophrenia, the use of 
different antipsychotic agents is found to be crucial and effec-
tive in symptom reduction, especially for positive symptoms 
and attention. Second-generation (atypical) antipsychotics 
showing less risk for extrapyramidal adverse effects and tar-
dive dyskinesia can be considered as the first-line treatment 
for acute psychosis. The second-generation antipsychotic 
clozapine is more effective in treating refractory schizo-
phrenia and suicidality.123 Other psychotropic drugs such as 
antidepressants and anticonvulsants can be used as an adjunct 
to antipsychotics to control specific psychiatric symptoms 
such as depression, anxiety, aggression, and impulsivity. 
Physical treatments, especially ECT, are found effective 
in controlling a few treatment-resistive symptoms such as 
catatonic state, strongly depressive and suicidal ideation, and 
some negative symptoms.107 Repetitive transcranial magnetic 
stimulation studies have demonstrated some promise in 
the treatment of schizophrenia, particularly for those with 
treatment-resistant auditory hallucinations and severe mood 
problems.124 Family psychoeducation (6–9 months) can reduce 
relapse rates, family burden, and treatment adherence.7
For ongoing management and later-stage schizophre-
nia, a variety of psychosocial interventions are found 
useful in reducing patients’ relapses and rehospitalizations, 
enhancing their functioning and medication adherence, and 
facilitating their rehabilitation and recovery. As indicated 
in Table 3, the more conclusive and consistent therapeutic 
interventions with moderate to large effect sizes in symp-
tom control, relapse prevention, and levels of psychosocial 
functioning included patient and/or family psychoeducation 
programs,125 cognitive–behavioral therapy,126 and an inte-
grated program with antipsychotics and different approaches 
to psychosocial care.127,128 Although small effect sizes to 
relapse prevention were found, a few commonly used 
approaches to psychosocial intervention for schizophrenia 
show increasingly consistent effects on specific patient out-
comes, such as patients’ social and community functioning 
being improved by social and vocational skills and short-
term competitive employment being enhanced by supported 
employment with work skills training.65,129
Similar to Amsterdam’s first-aid service in the 1970s, 
crisis intervention models for people with schizophrenia 
and other serious mental illnesses have at times emerged, 
aimed at treating psychiatric crises in the community and 
reducing relapses and/or the number of hospitalizations.129 
 Multidisciplinary, around-the-clock crisis intervention ser-
vices advocate prompt detection of symptom exacerbation 
and immediate intensive treatments as needed (eg, psychotro-
pic agents, individual and family counseling, psychological 
therapies, and practical assistance in activities of daily living) 
in both community and home settings. Programs in Australia 
and the United States, such as mobile crisis teams, crisis units 
in hospitals, crisis day treatment centers, and crisis residential 
programs, have been integrated into routine mental healthcare 
services.64,130 Nevertheless, recent clinical trials suggested 
that about half of the crisis intervention groups indicated 
nonsignificant effects on improvements in mental state or 
reducing hospitalization during the treatment period, as well 
as lacking evidence of their long-term benefits in terms of 
patient outcomes.131 In addition, recent research has also 
 evaluated the effectiveness of multifaceted illness manage-
ment programs consisting of a wide variety of biological/
physical, psychological, and social interventions and sug-
gested these programs might efficiently and effectively 
improve patient recovery and social reintegration.65,127,131
Conclusion
Antipsychotics (first- and/or second-generation antipsychot-
ics) are shown to be effective in reducing overall psychotic 
symptoms and relapse in patients with schizophrenia. It is 
therefore recommended in most of the literature as first-line 
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treatment for people with schizophrenia, at least in the 
short-term or at the acute stage of illness. However, the use 
of antipsychotics alone as the main treatment modality may 
be limited not only by their inability to tackle the frequently 
occurring negative symptoms and cognitive impairments but 
also by producing a wide variety of adverse effects in the 
internal body or organ functioning. The FGAs and second-
generation antipsychotics are two distinct classes of antipsy-
chotics with quite different potency and adverse effects, but 
these two classes do not have any definitive categorization 
between them in terms of efficacy, safety, and tolerability or 
in their clinical outcomes. However, because of the varied 
pharmacokinetics and patients’ treatment responsiveness 
across different agents, the medication regimen should be 
determined on an individual basis to ensure optimal effect in 
their long-term use. Other medical and psychological treat-
ments should be considered as an adjunct to antipsychotic 
agents. However, many of these alternative treatments are 
not strongly evidenced or conclusive in producing specific 
therapeutic effects in treating schizophrenia. More con-
trolled trials are recommended to enhance understanding 
about their efficacy as a monotherapy or in combined use 
with antipsychotics, other medication, and/or psychosocial 
interventions.
Many patients with schizophrenia often have unresolved 
life events and psychological distress, as well as illness-
related or drug-induced problems, which significantly affect 
their normalcy of daily life. In the last few decades, various 
models of psychosocial intervention have been developed and 
implemented as an adjunct to the pharmacological or other 
medical treatments at different stages of schizophrenia. The 
main purpose of these approaches to treatment is to provide 
these patients (and their family members) with adequate 
knowledge of and skills in this illness and its treatment 
and care, emotional support, problem-solving and coping 
skills, and/or enhancing cognitive and functional recovery. 
The current models commonly used for schizophrenia care 
include cognitive–behavioral therapy, psychoeducation, 
family intervention, social skills training, and cognitive 
remediation therapy. These psychosocial interventions and 
their comparative efficacy in treating people with schizophre-
nia will be discussed in another article. Recent systematic 
reviews on psychosocial interventions for schizophrenia 
have indicated significant positive medium-term (up to 
18 months) effects of a few approaches (eg, psychoeducation 
and cognitive–behavioral therapy) integrated or embedded 
into routine care (and medication use) in people with acute 
or chronic schizophrenia. To overcome the shortcomings 
of antipsychotics in the treatment of schizophrenia, clinical 
guidelines and standards of practice have recommended that 
a combination of treatment methods or modalities be adopted 
to meet the complex psychiatric and other health needs of 
people with schizophrenia. We are assured of and also highly 
recommend more research in the clinical efficacy of differ-
ent existing and new models of psychosocial interventions, 
together with antipsychotics or other psychotropic drugs, to 
ascertain a treatment approach for people with schizophre-
nia with the highest possible levels of efficacy, safety, and 
acceptability.
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